Aktis Oncology - About the company
Aktis Oncology is a public company based in Boston (United States), founded in 2021 by Stu Sjouwerman. It operates as a Developer of radiopharmaceuticals for solid tumor cancers. Aktis Oncology has raised $336M in funding from investors like EcoR1, Vida Ventures and Novartis. The company has 3299 active competitors, including 1118 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of radiopharmaceuticals for solid tumor cancers. The company had developed platforms to generate tumor-targeting agents for radiotherapy that are designed for high tumor penetration and long residence time. The therapeutic radioisotope molecules developed eliminates tumors from the body and minimize the side effects.
- Website
- www.aktisoncology.com/
- Email ID
- *****@aktisoncology.com
- Registered Address
- Rīga, Latgales iela 65 - 49
Key Metrics
Founded Year
2021
Location
Boston, United States
Stage
Public
Total Funding
$336M in 3 rounds
Latest Funding Round
Ranked
55th among 3299 active competitors
Employee Count
103 as on Aug 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Aktis Oncology
Aktis Oncology is associated with 4 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
AKTIS ONCOLOGY, INC. CIN: 32084554875 , United States, Active | Apr 29, 2022 | - | - | - |
AKTIS CIN: 40003104503 , Latvia, Active | Nov 30, 1992 | €0 - €1M (As on Dec 31, 2024) | 17 (As on Dec 31, 2022) | - |
AKTIS ONCOLOGY INC CIN: 852584233 , United States, Active | Dec 31, 1999 | - | 62 (As on Dec 31, 2024) | - |
AKTIS ONCOLOGY, INC. CIN: 85-2584233 , United States, Active | Aug 17, 2020 | - | 15 (As on Dec 31, 2021) | - |
Aktis Oncology's IPO details
Aktis Oncology got listed on Jan 09, 2026.
Click here to take a look at Aktis Oncology's IPO in detail
Sign up to download Aktis Oncology's company profile
Aktis Oncology's funding and investors
Aktis Oncology has raised a total funding of $336M over 3 rounds. Its first funding round was on Mar 18, 2021. Its latest funding round was a Series B round on Sep 20, 2024 for $*****. 7 investors participated in its latest round. Aktis Oncology has 18 institutional investors.
Here is the list of recent funding rounds of Aktis Oncology:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 20, 2024 | 9786338 | Series B | 6219444 | 9788864 | 5681449 | 7875934 |
Aug 25, 2022 | 1995830 | Series A | 8532604 | 9667281 | 3136181 | 7066098 |
Mar 18, 2021 | 6959916 | Series A | 4379903 | 9885772 |
Access funding benchmarks and valuations. Sign up today!View details of Aktis Oncology's funding rounds and investors
Aktis Oncology's founders and board of directors
Founder? Claim ProfileThe founders of Aktis Oncology is Stu Sjouwerman.
Here are the details of Aktis Oncology's key team members:
- Stu Sjouwerman: Co-Founder & COO of Aktis Oncology and founder of 2 other companies, Sunbelt Software and KnowBe4. Contact Info: 1 email address
View details of Aktis Oncology's Founder profiles and Board Members
Aktis Oncology's employee count trend
Aktis Oncology has 103 employees as of Aug 26. Here is Aktis Oncology's employee count trend over the years:
Uncover Aktis Oncology's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Aktis Oncology's Competitors and alternates
Top competitors of Aktis Oncology include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Aktis Oncology, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 80/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
55th |  Aktis Oncology 2021, Boston (United States), Public | Developer of radiopharmaceuticals for solid tumor cancers | $336M | 65/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Aktis Oncology's competitors? Click here to see the top ones
Aktis Oncology's Investments and acquisitions
Aktis Oncology has made no investments or acquisitions yet.
Reports related to Aktis Oncology
Here is the latest report on Aktis Oncology's sector:
News related to Aktis Oncology
Filter this listMedia has covered Aktis Oncology for a total of 8 events in the last 1 year, 3 of them have been about company updates.
•
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519GlobeNewswire•May 21, 2026•Aktis Oncology
•
Aktis Oncology Announces Clinical Imaging and Dosimetry Data for AKY-2519 at ASCOGlobeNewswire•Apr 22, 2026•Aktis Oncology
•
Aktis Oncology Announces FDA Clearance of IND Applications for AKY-2519GlobeNewswire•Mar 30, 2026•Aktis Oncology
•
Aktis Oncology major shareholder acquires 1,112,777 shares of stockInsiderTrades•Jan 15, 2026•Aktis Oncology
•
•
Aktis Oncology Announces Pricing of its Upsized Initial Public OfferingGlobeNewswire•Jan 09, 2026•Aktis Oncology
•
Aktis Oncology Nasdaq IPO to Raise $212 Million at $840 Million ValuationCaproasia•Jan 06, 2026•Aktis Oncology
•
Radiopharma-Focused Aktis Squeezes in IPO to End Biotech DroughtBioSpace•Dec 22, 2025•Aktis Oncology
•
Aktis Oncology starts Phase 1b trial of cancer drug Aky-1189.
PR Newswire•May 28, 2025•Aktis Oncology
•
Radiopharma biotech Aktis sees Big Pharma backers return for $175M series BFierce Biotech•Sep 30, 2024•Aktis Oncology, Bristol-Myers Squibb, MRLV, RA Capital Management and 5 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Aktis Oncology
Explore our recently published companies
- MERAKIOURENSE - Ourense based, 2019 founded, Unfunded company
- EXP Commercial Brokerage - Cincinnati based, 2021 founded, Unfunded company
- Radiance Partners - Mechanicsville based, 2021 founded, Unfunded company
- Evolvereo - United Kingdom based, 2025 founded, Unfunded company
- Maxim Zobov - Los Angeles based, Unfunded company
- Laz Villamil - Coral Gables based, Unfunded company
